FTY720 augments allogeneic but not syngeneic adoptive cell therapy. (A) Kaplan-Meyer survival plots of Renca-Her2/Neu-bearing mice. Mice (n = 12/group) were irradiated with 400 rads, and 1 day later either left untreated as a control (blue diamond), or injected with 30 × 106 transgenic T-bodies. Some groups received FTY720 0.3mg/kg intraperitoneally for 10 days after transfer. T cells were either: syngeneic T-bodies (Balb-N29, pink squares), syngeneic T-bodies with FTY720 (Balb-N29, purple squares), allogeneic T-bodies (Black-N29, orange triangles), allogeneic T-bodies with FTY720 (Black-N29, brown triangles, Black-N29+FTY720 vs Black-N29, P = .013). P values were computed separately for each experiment using the log-rank test and combined using the Fisher method. (B) FTY720 suppresses GVHD but augments ACT of high dose of allo–T-bodies. As in panel A, Renca-Her2/Neu-bearing mice, (n = 6/group) were irradiated with 400 rads, and 1 day later either left untreated as a control (blue diamond), or injected with 100 × 106 allogeneic T-bodies either with (brown triangles) or without FTY720 (orange triangles).
